Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, AB, Canada.
Faculty of Physical Education and Recreation, University of Alberta, Edmonton, AB, Canada.
Int J Cancer. 2018 Jul 15;143(2):253-262. doi: 10.1002/ijc.31307. Epub 2018 Feb 23.
Alcohol consumption has been declared a Group 1 carcinogen by the International Agency for Research on Cancer (IARC) and is a potential risk factor for several types of cancer mortality. However, evidence for an association with prostate cancer survival remains inconsistent. We examined how alcohol consumption post-diagnosis was associated with survival after prostate cancer diagnosis. Men diagnosed with prostate cancer (n = 829) in Alberta, Canada between the years 1997 and 2000 were recruited into a population-based case-control study and then followed for up to 19 years for survival outcomes. Pre- and post-diagnosis alcohol consumption, clinical characteristics and lifestyle factors were collected through in-person interviews shortly after diagnosis and again 2-3 years post-diagnosis. Cox proportional hazards were used to examine how post-diagnosis alcohol consumption was associated with all-cause and prostate cancer-specific mortality (competing risk analysis too), in addition to first recurrence/progression or new primary cancer. Most participants reported drinking alcohol (≥once a month for 6 months) post-diagnosis (n = 589, 71.0%). Exceeding Canadian Cancer Society (CCS) alcohol consumption recommendations (≥2 drinks/day) post-diagnosis was associated with prostate cancer-specific mortality relative to non-drinkers (aHR: 1.82, 95% CI: 1.07-3.10) with borderline evidence of a linear trend. Interestingly, those in the highest quartile of drinks/week pre- and post-diagnosis also had a twofold increase for prostate-specific mortality (aHR: 2.67, 95% CI: 1.28-5.56) while controlling for competing risks. Our results support post-diagnosis alcohol consumption was associated with increased mortality after prostate cancer diagnosis, specifically for prostate cancer-related death. Future studies focused on confirming this burden of disease are warranted.
酒精摄入已被国际癌症研究机构(IARC)列为 1 类致癌物质,是几种类型癌症死亡的潜在风险因素。然而,关于其与前列腺癌生存的关联证据仍不一致。我们研究了诊断后饮酒与前列腺癌诊断后生存的关系。2000 年在加拿大艾伯塔省诊断患有前列腺癌的男性(n=829)被纳入一项基于人群的病例对照研究,并在诊断后最多随访 19 年以了解生存结果。在诊断前后通过面对面访谈收集了饮酒、临床特征和生活方式因素,分别在诊断后不久和诊断后 2-3 年进行。使用 Cox 比例风险模型检查了诊断后饮酒与全因和前列腺癌特异性死亡率(也进行竞争风险分析)之间的关系,以及首次复发/进展或新发原发性癌症。大多数参与者报告在诊断后饮酒(≥每月 1 次,持续 6 个月)(n=589,71.0%)。与不饮酒者相比,诊断后超过加拿大癌症协会(CCS)饮酒建议(≥2 份/天)与前列腺癌特异性死亡率相关(校正后危险比[aHR]:1.82,95%可信区间[CI]:1.07-3.10),线性趋势有边界意义。有趣的是,诊断前后每周饮酒量最高四分位数的患者前列腺特异性死亡率也增加了两倍(aHR:2.67,95%CI:1.28-5.56),同时控制了竞争风险。我们的结果支持诊断后饮酒与前列腺癌诊断后死亡率增加相关,特别是与前列腺癌相关的死亡。需要进一步研究来证实这种疾病负担。